Journal articles: 'M. J. Brandenstein and Company'

1

Carfagno, Jacalyn Depasquale. "A History of the J. M. Maus Company." Arkansas Historical Quarterly 47, no. 1 (1988): 37. http://dx.doi.org/10.2307/40038132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Attwood, Margaret, and Chris Minett. "Book Reviews : The Learning Company Pedler, M., Burgoyne, J. and Boydell, T." Management Education and Development 23, no. 4 (December 1992): 365–66. http://dx.doi.org/10.1177/135050769202300410.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gopal, Sekar. "Strategic Interventions in Tackling Poor Performance of Service Departments: Study on Muhibbah Engineering (M) Bhd, Malaysia." Journal of Economics and Behavioral Studies 7, no. 4(J) (August 30, 2015): 6–13. http://dx.doi.org/10.22610/jebs.v7i4(j).589.

Full text

Abstract:

This case study describes the problems faced by Muhibbah Engineering (M) Bhd group of companies (Malaysia) due to the poor performance of itâ€™s service departments. This case was identified as a result of declining organizational performance of the company from the starting of year 2011 to early 2013. The main issues are declining profits (losses), delay in completing projects, customer complaints, skill depletion and poor organizational culture in the group besides other associated issues. The data related to the problems &issues are collected through personal discussions with the Project Directors of the company, companyâ€™s financial reports, financial research reports related to the company and through companyâ€™s website articles. The analysis is done on the inputs based on proven management concepts and theories such as leadership styles, organizational culture, span of control, performance management, human behavior and so on. The steps taken to mitigate the problems and the solutions are identifed through the changes made in the company through strategic interventions. The outcomes of each of the major interventions are recorded in this case study for the readers to understand and experiment them in similar and or different situations as the outcomes are positive and proven to be effective.

APA, Harvard, Vancouver, ISO, and other styles

4

OSNOWITZ, DEBRA. "A Company of One: Insecurity, Independence, and the New World of White-Collar Unemployment - By Carrie M. Lane." British Journal of Industrial Relations 50, no. 3 (August 10, 2012): 585–87. http://dx.doi.org/10.1111/j.1467-8543.2012.00901_3.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Oppenheimer, Carl H. "J. M. Sharpley, Elementary Petroleum Microbiology. 256 S., 95 Abb., 35 Tab. Texas. Houston 1966: Gulf Publishing Company Houston." Zeitschrift für allgemeine Mikrobiologie 7, no. 4 (January 24, 2007): 332. http://dx.doi.org/10.1002/jobm.19670070421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Grimmer, G. "Spektren von polycylischen Aromaten: Spectral Atlas of Polycyclic Aromatic Compounds. Von W. Karcher, J. R. Fordham, J. J. Dubois, P. G. J. M. Glaude und J. A. M. Ligthart. D. Reidel Publishing Company, Dordrecht - Boston - Lancaster (for the Commission o." Nachrichten aus Chemie, Technik und Laboratorium 33, no. 10 (October 1985): 895–96. http://dx.doi.org/10.1002/nadc.19850331012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zander, M. "Spectral Atlas of Polycyclic Aromatic Compounds. VonW. Karcher, R. J. Fordham, J. J. Dubois, P. G. J. M. Claude undJ. A. M. Lighthart. D. Reidel Publishing Company, Dordrecht 1985. 818 S., geb. $ 94.00. – ISBN 90–277-1652-8." Angewandte Chemie 98, no. 6 (June 1986): 577–78. http://dx.doi.org/10.1002/ange.19860980633.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Santoso, Halim Budi, Priyanka Ayu Sonia Putri, and Budi Sutedjo Dharma Oetomo. "Implementation of Sales Executive Dashboard for A Multistore Company in Yogyakarta." International Journal of New Media Technology 4, no. 1 (June 14, 2017): 59–68. http://dx.doi.org/10.31937/ijnmt.v4i1.540.

Full text

Abstract:

Information Technology is a part of strategic part for enterprise strategic planning. Information Technology can help the enterprise to determine its strategic planning. Through data from the past, thecompany can learn something and help to decide some strategic issue. A Multistore Company in Yogyakarta has more than five stores. The problem raises to generate real-time sales reporting. Sales manager and owner do not have access to real-time sales condition. To ease management analyzing and reporting sales condition, dimension model of the sales data needs to be built. This dimension model will help to make executive report from some dimensions mentioned in data warehouse. Sales data will pass through some processes: Extract, Transform, and Load (ETL) in order to prepare the data warehouse. This process is preprocessing data before dimensional model is built. In this research multi-dimensional modelling by taking data from 3 stores ranging from 1 February 2014 to 31 January 2015. By implementing sales executive dashboard, it helps to monitor and analyze sales condition. Dashboard shows graphic which ease user, especially sales manager and owner to learn current and updated sales condition based on dimensions: time, outlet / store, and product. Report gives detail information and multidimensionalhelps to analyze data from different perspective. Index Terms—Dashboard, Multi Dimentional Model, ETL, Executive Reporting REFERENCES[1] W. Eckerson, Performance Dashboard: Measuring,Monitoring, and Managing Your Business, New Jersey: JohnWiley & Sons, 2011. [2] O. Romero and A. Abello, "A Survey of MultidimensionalModelling Methodologies," International Journal of Data Warehousing and Mining, vol. 5, no. 2, pp. 1-23, 2009. [3] R. Kimball and J. Caserta, The Data Warehouse ETL Toolkit:Practical Techniques for Extracting, Cleaning, Conforming, and Delivering Data, Indianapolis: Wiley Publishing, Inc., 2004. [4] G. Dhillon and J. Backhouse, "Information System Security Management in the New Millenium," Communications of the ACM, vol. 43, no. 7, pp. 125-128, 2000. [5] C. Ballard, D. M. Farrell, A. Gupta, C. Mazuela and S. Vohnik, Dimensional Modelling: In a Business Intelligence Environment, IBM Redbooks, 2006. [6] E. Fernández-Medina, J. Trujillo and M. Piattini, "Modeldriven multidimensional modeling of secure datawarehouses," European Journal of Information Systems, vol. 16, no. 4, pp. 374-389, 2007. [7] E. Johnson and J. Jones, Building ETL Processes for Business Intelligence Solutions Built on Microsoft SQL Server, CA ERwin, 2007. [8] J. Mylopoulos, L. Liu and M. T. Owen, "Database Design," inEnsyclopedia of Database System, United States, Springer,2009, pp. 708 - 710. [9] K. R. Gadda and S. Dey, "Business Intelligence for PublicSector Banks in India: A Case study. Design, Development,and Deployment," Journal of Finance, Accounting and Management, vol. 5, no. 2, pp. 37-58, 2014. [10] D. J. Power, "DSS Resources," 6 June 2007. [Online]. Available: http://dssresources.com/. [Accessed 29 May 2017]. [11] D. Hedgebeth, "Data-driven decision making for the enterprise: an overview of business intelligence applications," The Journal of Information and Knowledge Management System, vol. 37, no. 4, pp. 414-420, 2007. [12] S. Williams and N. Williams, The Profit Impact of Business Intelligence, San Fransisco: Elsevier, 2007. [13] Imelda, "Business Intelligence," in Majalah Ilmiah Unikom, Bandung, UNIKOM, 2013, pp. 111-112.

APA, Harvard, Vancouver, ISO, and other styles

9

Lawrence, Christopher. "Horace Darwin's Shop: A History of the Cambridge Scientific Instrument Company, 1878-1968. M. J. G. Cattermole , A. F. Wolfe." Isis 80, no. 3 (September 1989): 546–47. http://dx.doi.org/10.1086/355138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mallory, George B. "Heart and lung transplantation 2000. Edited by J. B. O'Connell and M. P. Kaye, Austin Tx; R. G. Landes Company, 1993." Pediatric Pulmonology 19, no. 5 (May 1995): 319. http://dx.doi.org/10.1002/ppul.1950190513.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

O'Brien, Susan M., Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan Burger, Kristie Blum, Jeff Sharman, et al. "Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia." Blood 128, no. 22 (December 2, 2016): 233. http://dx.doi.org/10.1182/blood.v128.22.233.233.

Full text

Abstract:

Abstract Background: Ibrutinib (ibr), a first-in-class, once-daily Bruton's tyrosine kinase inhibitor, is approved by the US FDA for treatment of patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) including pts with del17p. The phase 1b/2 PCYC-1102 trial showed single-agent efficacy and tolerability in treatment-naïve (TN; O'Brien, Lancet Oncol 2014) and relapsed/refractory (R/R) CLL/SLL (Byrd, N Engl J Med 2013). We report efficacy and safety results of the longest follow-up to date for ibr-treated pts. Methods: Pts received 420 or 840 mg ibr QD until disease progression (PD) or unacceptable toxicity. Overall response rate (ORR) including partial response (PR) with lymphocytosis (PR-L) was assessed using updated iwCLL criteria. Responses were assessed by risk groups: unmutated IGVH, complex karyotype (CK; ≥3 unrelated chromosomal abnormalities by stimulated cytogenetics assessed by a reference lab), and in hierarchical order for del17p, then del11q. In the long-term extension study PCYC-1103, grade ≥3 adverse events (AEs), serious AEs, and AEs requiring dose reduction or discontinuation were collected. Results: Median age of the 132 pts with CLL/SLL (31 TN, 101 R/R) was 68 y (range, 37-84) with 43% ≥70 y. Baseline CK was observed in 41/112 (37%) of pts. Among R/R pts, 34 (34%) had del17p, 35 (35%) del11q, and 79 (78%) unmutated IGVH. R/R pts had a median of 4 prior therapies (range, 1-12). Median time on study was 46 m (range, 0-67) for all-treated pts, 60 m (range, 0-67.4) for TN pts, and 39 m (range, 0-67) for R/R pts. The ORR (per investigator) was 86% (complete response [CR], 14%) for all-treated pts (TN: 84% [CR, 29%], R/R: 86% [CR, 10%]). Median progression-free survival (PFS) was not reached (NR) for TN and 52 m for R/R pts with 60 m estimated PFS rates of 92% and 43%, respectively (Figure 1). In R/R pts, median PFS was 55 m (95% confidence intervals [CI], 31-not estimable [NE]) for pts with del11q, 26 m (95% CI,18-37) for pts with del17p, and NR (95% CI, 40-NE) for pts without del17p, del11q, trisomy 12, or del13q. Median PFS was 33 m (95% CI, 22-NE) and NR for pts with and without CK, and 43 m (95% CI, 32-NE) and 63 m (95% CI, 7-NE) for pts with unmutated and mutated IGVH, respectively(Figure 2). Among R/R pts, median PFS was 63 m (95% CI, 37-NE) for pts with 1-2 prior regimens (n=27, 3 pts with 1 prior therapy) and 59 m (95% CI, 22-NE) and 39 m (95% CI, 26-NE) for pts with 3 and ≥4 prior regimens, respectively. Median duration of response was NR for TN pts and 45 m for R/R pts. Pts estimated to be alive at 60 m were: TN, 92%; all R/R, 57%; R/R del17p, 32%; R/R del 11q, 61%; R/R unmutated IGVH, 55%. Among all treated pts, onset of grade ≥3 treatment-emergent AEs was highest in the first year and decreased during subsequent years. With about 5 years of follow-up, the most frequent grade ≥3 AEs were hypertension (26%), pneumonia (22%), neutropenia (17%), and atrial fibrillation (9%). Study treatment was discontinued due to AEs in 27 pts (20%) and disease progression in 34 pts (26%). Of all treated pts, 38% remain on ibr treatment on study including 65% of TN pts and 30% of R/R pts. Conclusions: Single-agent ibrutinib continues to show durable responses in pts with TN or R/R CLL/SLL including those with del17p, del11q, or unmutated IGVH. With extended treatment, CRs were observed in 29% of TN and 10% of R/R pts, having evolved over time. Ibrutinib provided better PFS outcomes if administered earlier in therapy than in the third-line or beyond. Those without CK experienced more favorable PFS and OS than those with CK. Ibrutinib was well tolerated with the onset of AEs decreasing over time, allowing for extended dosing for 65% of TN and 30% of R/R pts who continue treatment. Disclosures O'Brien: Janssen: Consultancy, Honoraria; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding. Furman:Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria, Speakers Bureau. Coutre:Janssen: Consultancy, Research Funding; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Research Funding; AbbVie: Research Funding. Flinn:Janssen: Research Funding; Pharmacyclics LLC, an AbbVie Company: Research Funding; Gilead Sciences: Research Funding; ARIAD: Research Funding; RainTree Oncology Services: Equity Ownership. Burger:Pharmacyclics, LLC, an AbbVie Company: Research Funding; Gilead: Research Funding; Portola: Consultancy; Janssen: Consultancy, Other: Travel, Accommodations, Expenses; Roche: Other: Travel, Accommodations, Expenses. Sharman:Gilead: Research Funding; TG Therapeutics: Research Funding; Acerta: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics: Research Funding; Celgene: Research Funding. Wierda:Abbvie: Research Funding; Genentech: Research Funding; Novartis: Research Funding; Acerta: Research Funding; Gilead: Research Funding. Jones:Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics, LLC, an AbbVie Company: Membership on an entity's Board of Directors or advisory committees, Research Funding. Luan:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment, Other: Travel, Accommodations, Expenses. James:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment. Chu:Pharmacyclics, LLC, an AbbVie Company: Employment; AbbVie: Equity Ownership.

APA, Harvard, Vancouver, ISO, and other styles

12

Borsdorf, R. "W. Karcher, R. J. Fordham, J. J. Dubois, P. G. J. M. Glaude, J. A. M. Ligthart (Hrsg.). Spectral atlas of polycyclic aromatic compounds. D. Reidel Publishing Company, Dordrecht/Boston/Lancaster 1985, 818 S., Preis: 94 US $/Dfl. 280.00/£77.75. SBN 90-277-1652-8." Crystal Research and Technology 22, no. 9 (September 1987): K158. http://dx.doi.org/10.1002/crat.2170220932.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Penaskovic, Richard. "After The Sheiks: The Coming Collapse of the Gulf Monarchies. By Christopher M. Davidson. Pp. xiii, 298, London, Hurst & Company, 2012, £29.99." Heythrop Journal 54, no. 3 (April 8, 2013): 454–55. http://dx.doi.org/10.1111/j.1468-2265.2013.00790_101.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Giebelhaus, August W. "The R. J. Reynolds Tobacco Company. By Nannie M. Tilley. (Chapel Hill: University of North Carolina Press, 1985. xxi + 706 pp. $35.00.)." Business History Review 60, no. 2 (1986): 311–12. http://dx.doi.org/10.2307/3115322.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Kim, Seon, and Kevin P. Lyness. "Gottman, J.S., & Gottman, J. M. (2015). 10 principles for doing couples therapy. New York, NY: W.W. Norton & Company, 258 pp., $24.95." Journal of Marital and Family Therapy 43, no. 2 (April 2017): 364–65. http://dx.doi.org/10.1111/jmft.12226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Siregar, Ulfah J., and Wirrahma . "GROWTH OF FOUR FAST GROWING TREE SPECIES ON TAILINGS MEDIA FROM GOLD MINING COMPANY PT ANTAM UBPE PONGKOR." Journal of Tropical Silviculture 7, no. 3 (December 28, 2016): S68—S71. http://dx.doi.org/10.29244/j-siltrop.7.3.s68-s71.

Full text

Abstract:

Tailing from mining activity contains heavy metal that can be managed by phytoremediation. Plant selection to be used in phytoremediation plays important role that determine the success of these activities. The objective of this research is to study the growth of four forest tree species in media containing tailings from gold mining. Four fast growing tree species, i.e. Swietenia macrophylla King., Anthocephalus macrophyllus (Roxb.) Havil., Maesopsis eminii Engl., and Toona sureni (Blume) Merr., and two kinds of growing media, i.e. tailings and mixture of tailings + compost with 3:1 ratio, were used in a Completely Randomized Factorial Design. The growth parameters measured were plant height and diameter, leaf length and width, number of leaves, stomata density, total wet and dry biomass, also root-shoot ratio, and percentage of survival. The results of the research showed that plant types significantly affect all parameters observed. Media treatment had significant effect on total wet and dry biomass only. Interaction between plant types and media gave significant effect only on total wet biomass. Based on survival and growth parameter observed A. macrophyllus gave best performance.Key words: A. macrophyllus, M. eminii, phytoremediation, S. macrophylla, tailings, T. sureni

APA, Harvard, Vancouver, ISO, and other styles

17

Homer-Vanniasinkam, S. "New trends and developments in carotid artery disease. A. Branchereau and M. Jacobs (eds). 278 × 216 mm. Pp. 284. Illustrated. 1998. Armonk, New York: Futura Publishing Company." British Journal of Surgery 86, no. 2 (February 1999): 285. http://dx.doi.org/10.1046/j.1365-2168.1999.1000e.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Baskett, P. J. F. "Techniques and procedures in critical care. R. W. Taylor, J. M. Civetta, R. R. Kirby. 185 × 232mm. Pp. 418. Illustrated. 1989. Philadelphia: J. B. Lippincott Company. $95.00 softback." British Journal of Surgery 77, no. 10 (October 1990): 1196. http://dx.doi.org/10.1002/bjs.1800771048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Moen, Phyllis. "A Company of One: Insecurity, Independence, and the New World of White-Collar Unemployment by Carrie M. Lane. Ithaca, NY: Cornell University Press (ILR Press), 2011." Anthropology of Work Review 33, no. 2 (November 27, 2012): 131–32. http://dx.doi.org/10.1111/j.1548-1417.2012.01085_4.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Wood, David, and Saeid Mokhatab. "Petroleum Reservoir Simulations: A Basic Approach, J. H. Abou-Kassem, S. M. Farouq Ali, and M. R. Islam, Gulf Publishing Company, Houston, Texas, USA, 2006, 480 pages ISBN: 0-9765113-6-3." Energy Sources, Part A: Recovery, Utilization, and Environmental Effects 29, no. 12 (June 19, 2007): 1159. http://dx.doi.org/10.1080/15567030701499048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Burns, Malcolm R. "The R. J. Reynolds Tobacco Company. By Nannie M. Tilley. Chapel Hill, North Carolina: University of North Carolina Press, 1985, Pp. xxi, 706. $35.00." Journal of Economic History 45, no. 4 (December 1985): 1005–6. http://dx.doi.org/10.1017/s0022050700035464.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Walker, Retia Scott. "Book Reviews : Mary M. Ball and Frank J. Whittingham, Surviving Dependence: Voices of African-American Elders. Amityville, NY. Baywood Publishing Company, 1995. $49.95 hardback." Journal of Applied Gerontology 15, no. 2 (June 1996): 269–71. http://dx.doi.org/10.1177/073346489601500210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Nermut, M. V. "M. R. J. Salton, The bacterial Cell Wall. 293 S., 77 Abb., 67 Tab. Amsterdam, London, New York 1964: Elsevier Publishing Company. DM 44,50." Zeitschrift für allgemeine Mikrobiologie 5, no. 3 (January 24, 2007): 252. http://dx.doi.org/10.1002/jobm.19650050310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

GAREY, L. "Fundamental neuroanatomy By W. J. H. Nauta and M. Feirtag. New York: W. H. Freeman and Company. (1986). 340 pp. Cloth $39.95; Paper $26.95." Cell 44, no. 3 (February 1986): 380. http://dx.doi.org/10.1016/0092-8674(86)90458-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Іванова, Зоя Олегівна, and Володимир Олегович Іванов. "ОСОБЛИВОСТІ МАРКЕТИНГОВОЇ КОМУНІКАЦІЙНОЇ ДІЯЛЬНОСТІ ПІДПРИЄМСТВА З ВИКОРИСТАННЯМ ЦИФРОВИХ ІНСТРУМЕНТІВ ТА ТЕХНОЛОГІЙ." Bulletin of the Kyiv National University of Technologies and Design. Series: Economic sciences 139, no. 5 (April 3, 2020): 32–39. http://dx.doi.org/10.30857/2413-0117.2019.5.3.

Full text

Abstract:

The authors seek to explore the importance of implementing marketing communications in modern business settings. The article offers insights into specific features of marketing communications and their essential role in company activities, being a critical factor that impacts on company competitiveness, creating its positive image among consumers, disseminating information about company products and services, etc. The research provides interpretations of the classic concepts of "communication", "marketing communication", "digital communication" along with presenting modern digital technologies of marketing communications. Based on the analysis of scientific literature, the major benefits of digital communications have been revealed, in particular: their interactivity, personalization and measurability. Also, a comparative overview of traditional and digital marketing communications is provided. Resting upon the works of N. Illiashenko, O. Savchenko, M. Stelnzer, J. Wubben, D. Khalilov, the authors suggest the basic tools of digital communications as well as providing the main advantages and disadvantages in their application. Particular emphasis is placed on the benefits of modern digital technologies of marketing communications (3D technologies; augmented reality (AR); virtual reality (VR); QR code). To achieve the most effective results from the implementation of digital tools and technology for sales promotion, it is critical to design a clear and specific marketing communication program that will contribute to developing a detailed marketing plan and build a company strategy for the future.

APA, Harvard, Vancouver, ISO, and other styles

26

Newbury, Colin. "Technology, Capital, and Consolidation: The Performance of De Beers Mining Company Limited, 1880–1889." Business History Review 61, no. 1 (1987): 1–42. http://dx.doi.org/10.2307/3115773.

Full text

Abstract:

In this article, Dr. Newbury focuses on the technical and financial reasons for amalgamation at the Kimberley mines in South Africa, drawing on primary records to account for the rise of De Beers as the world's major diamond mining company in the 1880s. He finds that prior experience in local government and on the mining boards prepared company directors for competition in joint stock enterprise, while differences in production policies and performance influenced the pattern of mergers within and among the four Kimberley mines. De Beers's close relationship with diamond merchants and private banks in London, particularly N. M. Rothschild & Sons, was central to its position as a prime mover toward consolidation. Dr. Newbury views De Beers as a firm that relied for its success less on its renowned chairman, Cecil J. Rhodes, than on a combined managerial expertise that reflected the interests of both mining producers and merchant buyers.

APA, Harvard, Vancouver, ISO, and other styles

27

Pollock, George H. "J. M. Charcot, MD, with Additional Lectures by A. Loomis, MD. Translated by Leigh H. Hunt, MD. New York: William Wood Company, 1881. 280 pp." International Psychogeriatrics 6, no. 1 (March 1994): 121–22. http://dx.doi.org/10.1017/s1041610294211687.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Klein, Milton S. "Book Review: Handbook of Hemodynamic Monitoring Edited by J. M. Gore, J. S. Alpert, J. R. Benotti, P. W Kotilainin, and C. I. Haffajee Boston, Little, Brown and Company, 1985 167 pp, illustrated, $13.95." Journal of Intensive Care Medicine 1, no. 2 (March 1986): 119. http://dx.doi.org/10.1177/088506668600100208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Sari, Maya, Netti Siska N, and S. Sulastri. "Firm Size as Moderator to Capital Structure-Its Determinants Relations." GATR Journal of Finance and Banking Review 4, no. 3 (December 23, 2019): 108–15. http://dx.doi.org/10.35609/jfbr.2019.4.3(4).

Full text

Abstract:

Objective – Capital structure policy is a strategic decision related to the selection of funding sources. The best mixed of capital structure will produce a low cost of capital, which in turn can maximize the value of the company. This study aims to determine the effect of company size as a moderator on the relationship of capital structure and its determinant factors on manufacturing companies in Indonesia and Malaysia. Methodology – Data were collected from 40 manufacturing companies listed on the Indonesia Stock Exchange and 130 manufacturing companies listed on the Bursa Malaysia during 2008-2017. This study will analyze the determinants of capital structure consisting of liquidity, profitability, tangibility and efficiency as well as company size as a moderating variable. The research method uses panel data regression. Findings – The company size provides a moderating effect on the relationship between capital structure with liquidity, profitability, tangibility and efficiency, and this moderation effect is strengthened in large companies in Indonesia. Instead, this moderation effect is weakening for large companies in Malaysia Novelty – Research shows that the "modified pecking order" model is better able to explain the capital structure, policies of manufacturing companies in Indonesia and Malaysia compared to the traditional pecking order and trade off theory models. Type of Paper: Empirical Keywords: Capital Structure; Pecking Order Theory; Trade Off Theory; Manufacturing Company; Moderating Effect. Reference to this paper should be made as follows: Sari, M; Netti, S.N; Sulastri, S. 2019. Firm Size as Moderator to Capital Structure-Its Determinants Relations, J. Fin. Bank. Review 4 (3): 108–115 https://doi.org/10.35609/jfbr.2019.4.3(4) JEL Classification: G23, G30, G32.

APA, Harvard, Vancouver, ISO, and other styles

30

Istan, Muhammad, and Kamaludin Kamaludin. "Political Patronage on Capital Structure in Indonesia." GATR Journal of Finance and Banking Review 4, no. 3 (December 23, 2019): 89–97. http://dx.doi.org/10.35609/jfbr.2019.4.3(2).

Full text

Abstract:

Objective – The purpose of this research is to test the theory of capital structure by determining whether the relationship is affected by Political Patronage. The study will examine political support, capital structure and financial performance of the company. Methodology/Technique – The data in this research is in the form of financial ratios displayed in the financial report of each company listed from 2010 to 2016. The sample was selected using purposive sampling with as many as 70 companies indicated to have political support. The data was analysed using regression analysis. Findings – The results show that Political Patronage has an influence on capital structure and political Patronage has a weak effect on financial performance. Type of Paper: Empirical Keywords: Political Patronage; Capital Structure; Financial Performance. Reference to this paper should be made as follows: Istan, M; Kamaludin. 2019. Political Patronage on Capital Structure in Indonesia, J. Fin. Bank. Review 4 (3): 89 – 97 https://doi.org/10.35609/jfbr.2019.4.3(2) JEL Classification: G30, G32, G39.

APA, Harvard, Vancouver, ISO, and other styles

31

Nowell, W. B., C. L. Kannowski, K. Gavigan, Z. Cai, A. Cardoso, T. Hunter, S. Venkatachalam, J. Birt, J. Workman, and J. Curtis. "PARE0026 WHICH PATIENT-REPORTED OUTCOMES DO RHEUMATOLOGY PATIENTS FIND IMPORTANT TO TRACK DIGITALLY? A REAL-WORLD LONGITUDINAL STUDY IN ARTHRITISPOWER." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1298.1–1299. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1016.

Full text

Abstract:

Background:Development of a standardized approach to assess key elements of disease activity in rheumatology clinical trials has been the goal of Outcome Measures in Rheumatology Clinical Trials (OMERACT), American College of Rheumatology (ACR), and European League Against Rheumatism (EULAR).1,2,3The core sets of measures developed include assessments and composite indices incorporating use of patient-reported outcomes (PROs) and clinical measures and clinicians’ assessments to quantify disease activity over time.2PROs are important indicators of disease activity and variability, and they are increasingly used to evaluate treatment effectiveness. Little is known about PROs that patients with rheumatic conditions find most important to convey their experience with their condition and its treatment.Objectives:To examine PROs selected by patients with rheumatic conditions in the ArthritisPower registry to identify symptoms they found most important to track digitally.Methods:Adult US patients within the ArthritisPower registry with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), osteoporosis (OP), osteoarthritis (OA), and fibromyalgia syndrome (FMS) were invited via email to participate in this study. Enrolled participants (pts) were prompted to select ≤10 PRO symptom measures they felt were important to track for their condition at baseline via the ArthritisPower app. At 3 subsequent time points (Month [m] 1, m2, m3), pts were given the option to continue tracking their previously selected PRO measures or to add, remove and/or select different measures. At m3, pts completed an exit survey to prioritize ≤5 measures from all measures selected during study participation and to specify other symptoms not available that they would have wanted to track. Measures were rank-ordered based on number of pts rating the item as their 1st, 2nd, 3rd, 4th or 5th choice and weighted by multiplying the rank number by its inverse for a single, weighted summary score for each measure. Values were summed across all pts to produce a summary score for each measure.Results:Among pts who completed initial selection of PRO assessments at baseline (N=253), 184 pts confirmed or changed PRO selections across m1-3. Mean (SD) age of pts was 55.7 (9.2) yrs, 89.3% female, 91.3% White, mean disease duration of 11.6 (10.6) yrs. The majority (64.8%) self-reported OA, followed by RA (48.6%), FMS (40.3%), PsA (26.1%), OP (21.0%), AS (15.8%) and SLE (5.9%), not mutually exclusive, and were similar to the overall ArthritisPower population. The average number of instruments (SD) selected for baseline completion was 7.0 (2.5), 7.1 (2.4) at m1, 7.2 (2.4) at m2, and 7.0 (2.5) at m3. The top 5 PROs ranked by pts overall as most important (weighted summary score) for tracking were Fatigue (71), Physical Function (58), Pain Intensity (50), Pain Interference (49), Duration of Morning Joint Stiffness (41) (Figure 1). Fatigue, Physical Function, and Pain were consistently in the top 5 across diseases while Depression was more frequent among pts with OA, AS and FMS. Pts’ PRO selections showed stability over time except for the RA Flare measure which decreased from 70.5% of RA pts at baseline to 13.6% at m3.Conclusion:The symptoms prioritized by pts included fatigue, physical function, pain, and joint stiffness. Pts‘ choices were consistent over time. These findings provide insights into symptoms rheumatology patients find most important and will be useful to inform design of future patient-centric clinical trials and real-world evidence generation.References:[1]Boers M, et al. J Rheumatol Suppl. 1994;41:86–89.[2]Felson DT, et al. Arthritis Rheum. 1993;36:729–740.[3]Tugwell P, et al. J Rheumatol. 1993;20:555–556.Disclosure of Interests:W. Benjamin Nowell: None declared, Carol L. Kannowski Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Kelly Gavigan: None declared, Zhihong Cai Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Anabela Cardoso Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Theresa Hunter Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Shilpa Venkatachalam: None declared, Julie Birt Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jennifer Workman Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jeffrey Curtis Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB

APA, Harvard, Vancouver, ISO, and other styles

32

Jellinger, K. A. "Vascular Dementia. John Stirlin Meyer, Giane M. Rauch, Helmut Lechner and Carlo Loeb, eds. Futura Publishing Company, Inc., Amonk, NY, USA 2001, 320 pp., ISBN 0-87993-425-5, US$ 88.00." European Journal of Neurology 8, no. 6 (November 14, 2001): 734–35. http://dx.doi.org/10.1046/j.1468-1331.2001.0311c.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Ali, M. "Tertiary enrichment of a manganese oxide tailings material using heavy medium separation (HMS)." Bangladesh Journal of Scientific and Industrial Research 49, no. 1 (May 8, 2014): 35–40. http://dx.doi.org/10.3329/bjsir.v49i1.18852.

Full text

Abstract:

A study was conducted on the enrichment of manganese oxide tailings material generated from sorting spiral concentration at Ghana Manganese Company (GMC) Limited, Nsuta. The investigation explored mineralogical and particle size characterisation and heavy medium separation technique. Analytical methods used include; X-Ray Fluorescence and Atomic Absorption Spectrometry (AAS). The material contained 9.01% Al2O3, 27.43 % SiO2, 23.64% MnO2 and 9.86% Fe2O3, the other oxides range between 0.04 to 1.55 %. By treating the individual size fractions at a bath density of 2.96, the highest ratio of concentration of 3.56 was obtained at 180 ?m, while the highest enrichment ratio of 1.84 and manganese grade of 38.25% were obtained at 1180?m respectively. These qualify the enriched material as suitable for Ferro-alloy industry. DOI: http://dx.doi.org/10.3329/bjsir.v49i1.18852 Bangladesh J. Sci. Ind. Res. 49(1), 35-40, 2014

APA, Harvard, Vancouver, ISO, and other styles

34

McDowell, Richard L. "Clinical Chemistry: Principles, Procedures, Correlations. M. J. Bishop, J. L. Duben-Von Laufen, E. P. Fody, Eds., J. P. Lippincott Company, Philadelphia, PA 19105, April 1985, xviii + 604 pp, $42.50. ISBN 0-397-50662-7." Clinical Chemistry 32, no. 9 (September 1, 1986): 1793. http://dx.doi.org/10.1093/clinchem/32.9.1793.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Schotte, Remko, Julien Villaudy, Greta De Jong, Viviana Neviani, Wouter Pos, Sophie E. Levie, Daniel M. Go, et al. "Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL." Blood 136, Supplement 1 (November 5, 2020): 41–42. http://dx.doi.org/10.1182/blood-2020-134088.

Full text

Abstract:

Despite recent advances in treatment of B-acute lymphoblastic leukemia (B-ALL) there is still a need for novel targeted therapies. The tetraspanin CD9 is expressed in 60-80% of B-ALL and correlates with adverse prognosis. Recently, the mouse CD9 antibody ALB6 was shown to induce leukemia rejection in NOD/SCID mice. However, clinical development of ALB6 and other CD9-targeting antibodies was hampered by their CD9 mediated induction of platelet aggregation. It is known that CD9 is still expressed on tumor cells after treatment with chemotherapy or blinatumomab (Leung, 2019; Linder, 2016). AT1412 is a fully human antibody isolated from B cells of a patient that was cured from stage IV metastatic melanoma (Verdegaal, 2011). AT1412 targets CD9, without inducing platelet aggregation in vitro or thrombosis in cynomolgus monkeys after intravenous administration at therapeutic dose levels. By crystallography AT1412 was shown to bind a unique epitope preventing homodimerization of CD9, distinctly different from other CD9 antibodies. AT1412 binds a majority of patient B-ALL samples, but not T-ALL and induces ADCC and ADCP of CD9 positive B-ALL primary cells and the level of cytotoxicity significantly correlated with that of AT1412 binding. In both NSG and immunodeficient mice harboring a human immune system (HIS mice) AT1412 demonstrated a strong, dose-dependent tumor rejection of B-ALL, most pronounced in the extramedullary sites. In HIS mice AT1412 treatment led to an accumulation of T cells and CD14+ myeloid cells at the tumor sites. To support clinical development, pre-clinical safety of AT1412 was evaluated in cynomolgus monkeys. AT1412 demonstrated a half-life of 8.5 days, supporting 2-3 weekly administration in humans. Besides transient thrombocytopenia no other pathological deviations were observed. No effect on coagulation parameters, bruising or bleeding were observed macro- or microscopically. The thrombocytopenia is reversible, and its recovery accelerated in those animals developing anti-drug antibodies. Taken together, we demonstrate that CD9 on B-ALL cells can be successfully targeted by AT1412. AT1412 targets a unique epitope and does not induce thrombosis. Pre-clinical safety assessment is supporting that AT1412 can be safely administered. A First in Human clinical study is scheduled to start early 2021 in human solid tumors to determine safety and efficacy. AT1412 efficacy will be evaluated in B-ALL in expansion cohorts. Leung, K.T., Zhang, C., Chan, K.Y.Y., Li, K., Cheung, J.T.K., Ng, M.H.L., Zhang, X.-B., Sit, T., Lee, W.Y.W., Kang, W., et al. (2019). CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity. Leukemia. Linder, K., Gandhiraj, D., Hanmantgad, M., Seiter, K., and Liu, D. (2016). Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: HyperCVAD, high dose cytarabine mitoxantrone and CLAG. Exp. Hematol. Oncol. 5, 5-8. Verdegaal, E.M.E., Visser, M., Ramwadhdoebé, T.H., van der Minne, C.E., van Steijn, J. a Q.M.J., Kapiteijn, E., Haanen, J.B. a G., van der Burg, S.H., Nortier, J.W.R., and Osanto, S. (2011). Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol. Immunother. 60, 953-963. Disclosures Schotte: AIMM Therapeutics: Current Employment, Current equity holder in private company. Villaudy:AIMM Therapeutics: Current Employment, Current equity holder in private company. Levie:AIMM Therapeutics: Current Employment, Current equity holder in private company. Go:AIMM Therapeutics: Current Employment, Current equity holder in private company. Yasuda:AIMM Therapeutics: Current Employment, Current equity holder in private company. Frankin:AIMM Therapeutics: Current Employment, Current equity holder in private company. Cercel:AIMM Therapeutics: Current Employment, Current equity holder in private company. van Hal-van Veen:AIMM Therapeutics: Current Employment, Current equity holder in private company. van de Berg:AIMM Therapeutics: Current Employment, Current equity holder in private company. Fatmawati:AIMM Therapeutics: Current Employment, Current equity holder in private company. Kedde:AIMM Therapeutics: Current Employment, Current equity holder in private company. Claassen:AIMM Therapeutics: Current Employment, Current equity holder in private company. Rijneveld:Amgen: Research Funding; Servier: Research Funding. Spits:AIMM Therapeutics: Current equity holder in private company, Ended employment in the past 24 months, Membership on an entity's Board of Directors or advisory committees. van Eenennaam:AIMM Therapeutics: Current Employment, Current equity holder in private company.

APA, Harvard, Vancouver, ISO, and other styles

36

Rudge, C. J. "Current urologic therapy (no. 3). E. J. Seidmon and P. M. Hanno (eds). 265 × 185 mm. Pp 562. Illustrated. 1994. Philadelphia: W. B. Sounders Company. £69." British Journal of Surgery 82, no. 4 (April 1995): 572. http://dx.doi.org/10.1002/bjs.1800820455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Geng, Xin, Radu Mihaila, Yue Yuan, Steven Strutt, Jörg Benz, Tzechiang Tang, Christina Mayer, and Donna Oksenberg. "Inclacumab, a Fully Human Anti-P-Selectin Antibody, Directly Binds to PSGL-1 Binding Region and Demonstrates Robust and Durable Inhibition of Cell Adhesion." Blood 136, Supplement 1 (November 5, 2020): 10–11. http://dx.doi.org/10.1182/blood-2020-140530.

Full text

Abstract:

Sickle cell-related vaso-occlusive crises (VOCs) are among the primary clinical manifestations of sickle cell disease (SCD) and are associated with many acute and chronic complications that lead to significant morbidity and mortality. VOCs are caused by the adhesion of leukocytes and sickle erythrocytes to the endothelium, which results in vascular obstruction and tissue ischemia. By blocking the P-selectin- PSGL-1 (P-selectin glycoprotein ligand 1) mediated cell adhesion, crizanlizumab, a recently FDA approved humanized IgG2 anti-P-selectin antibody, reduced the frequency of VOCs in SCD patients and established the proof of principle for this approach (Ataga KI et al., N Engl J Med, 2017). Inclacumab is a novel, fully human IgG4 monoclonal antibody that selectively targets P-selectin and has safely demonstrated sustained anti-cell adhesion effects in over 700 participants including healthy volunteers and patients with cardiovascular disease (Schmitt C et al., J Cardiovasc Pharmacol. 2015; Tardif JC et al., J Am Coll Cardiol, 2013; Morrison M et al., Eur J Clin Pharmacol, 2015; Kling D et al., Thromb Res, 2013). A crystal structure of inclacumab and P-selectin reveals that inclacumab directly binds to an epitope in the PSGL-1 binding region on P-selectin and thus competitively inhibits P-selectin and its ligand interaction. In contrast, crizanlizumab binds to a more distant epitope to the PSGL-1 binding site on P-selectin. To further elucidate differences between the two antibodies, we characterized inclacumab and crizanlizumab in a series of in vitro functional assays including ligand binding affinity, competitive ligand binding by surface plasmon resonance (SPR), P-selectin mediated cell-based adhesion assay and cell-cell interaction with human whole blood samples. In vitro, inclacumab binds to human P-selectin with high affinity and potently suppresses the interaction of P-selectin with its main ligand PSGL-1. Both antibodies exhibited similar binding affinities to P-selectin (KD of 9.9 and 9.1 nM for inclacumab and crizanlizumab, respectively) and comparable potencies at preventing a PSGL-1 mimetic peptide from binding P-selectin (IC50 of 1.9 and 2.2 µg/mL for inclacumab and crizanlizumab, respectively) or blocking the adhesion of PSGL-1 expressing cells to an immobilized P-selectin (IC50 = 430 ng/mL for inclacumab and IC50 = 453 ng/mL for crizanlizumab). However, inclacumab demonstrated greater maximal platelet-leukocyte cell adhesion inhibition in response to thrombin receptor activating peptide (TRAP) in blood samples from both healthy volunteers and subjects with SCD in an in vitro efficacy assay (see figure). Inclacumab is differentiated from crizanlizumab as a fully human monoclonal antibody that directly blocks the PSGL-1 binding region of P-selectin and shows greater maximal inhibition of cell-cell interactions in vitro. At doses up to 20 mg/kg Q4W, which previous clinical trials have shown to be safe and well-tolerated, inclacumab has much greater drug exposure than the approved dose of crizanlizumab (5 mg/kg W0/W2/Q4W) (Ataga KI et al., N Engl J Med, 2017; Schmitt C et al., J Cardiovasc Pharmacol. 2015; Tardif JC et al., J Am Coll Cardiol, 2013). A single dose of inclacumab 20 mg/kg demonstrated full PLA inhibition for ≥84 days in healthy volunteers (Morrison M et al., Eur J Clin Pharmacol, 2015; Kling D et al., Thromb Res, 2013). Inclacumab may allow for a substantially longer and therefore more convenient dosing interval as compared with crizanlizumab. In aggregate, these data suggest that inclacumab has the potential to be a best-in-class P-selectin inhibitor to reduce VOCs in sickle cell disease. Clinical studies of inclacumab in patients with SCD are planned for the 1st half of 2021. Disclosures Geng: Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Mihaila:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Yuan:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Strutt:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Benz:Roche Pharmaceuticals: Current Employment. Tang:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Mayer:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Oksenberg:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company.

APA, Harvard, Vancouver, ISO, and other styles

38

Samudro, Andreas, Ujang Sumarwan, Megawati Simanjuntak, and Eva Z. Yusuf. "How Commitment, Satisfaction, and Cost Fluctuations Influence Customer Loyalty." GATR Journal of Management and Marketing Review 4, no. 2 (June 25, 2019): 115–25. http://dx.doi.org/10.35609/jmmr.2019.4.2(3).

Full text

Abstract:

Objective – The purpose of this study is to investigate which factors have a stronger influence on final purchase decisions from the perspective of the chemical market. The factors under consideration are customer satisfaction, commitment and cost fluctuations. Methodology/Technique – By understanding the factors that influence purchase decisions, a chemical company or other industrial company can place greater focus on the factors that will improve or enhance customer loyalty. The research design is a conclusive-descriptive and quantitative method. Findings & Novelty – The results of the analysis confirm that customer commitment and satisfaction have a stronger influence on customer loyalty, compared to fluctuating costs. Satisfaction does not have a direct influence on loyalty, except where commitment is used as a mediator. Type of Paper: Empirical Keywords: Satisfaction; Commitment; Switching Cost; Loyalty; B2B Relationship. Reference to this paper should be made as follows: Samudro, A.; Sumarwan, U.; Simanjuntak, M.; Yusuf, E. Z. 2019. How Commitment, Satisfaction, and Cost Fluctuations Influence Customer Loyalty, J. Mgt. Mkt. Review 4 (2): 115 – 125 https://doi.org/10.35609/jmmr.2019.4.2(3) JEL Classification: M10, M12, M19, M30.

APA, Harvard, Vancouver, ISO, and other styles

39

Yoo, Hana. "Gottman, J. M., & Gottman, J. S. (2018). The science of couples and family therapy: Behind the scenes at the Love Lab. New York, NY: W.W. Norton & Company, 340 pp., $35." Journal of Marital and Family Therapy 45, no. 1 (January 2019): 186–87. http://dx.doi.org/10.1111/jmft.12342.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Darzins, Peteris. "The Science of Geriatrics. VOLS. 1&2. J. E. Morley, H. J. Armbrecht, R. M. Coe, and B. Vellas (Eds.). New York: Springer Publishing Company, 2001, 720 pp., $US 139.00 (softcover)." International Psychogeriatrics 15, no. 1 (March 2003): 90. http://dx.doi.org/10.1017/s1041610203228787.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Frosch, William A. "Effective Therapy With Borderline Patients: Case Studies—by Robert J. Waldinger, M. D., and John G. Gunderson, M. D.; Washington, D. C., American Psychiatric Press, 1989, 232 pages, $27.50; originally published by Macmillan Publishing Company, 1987." Psychiatric Services 42, no. 5 (May 1991): 543. http://dx.doi.org/10.1176/ps.42.5.543.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Frost, Elizabeth A. M. "Trauma Anesthesia and Critical Care of Neurological Injury. Kenneth J. Abrams and Christopher M. Grande, editors. Futura Publishing Company, Inc., Mount Kisco, NY, 553 pp., illustrated. $98.00." Journal of Neurosurgical Anesthesiology 10, no. 2 (April 1998): 127. http://dx.doi.org/10.1097/00008506-199804000-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kowalski, Marian. "The quantum and electromagnetic process of photon emission by the hydrogen atom." Physics Essays 34, no. 2 (June 7, 2021): 116–49. http://dx.doi.org/10.4006/0836-1398-34.2.116.

Full text

Abstract:

Light emitted from atoms during transitions of electrons from higher to lower discrete states has the form of photons carrying energy and angular momentum. This paper considers the process of emission of a single photon from the hydrogen atom by using quantum theory and Maxwell's equations [W. Gough, Eur. J. Phys. 17, 208, 1996; L. D. Landau and E. M. Lifshitz, Quantum Mechanics (Pergamon Press, Oxford, 1965); J. D. Jackson, Classical Electrodynamics (John Wiley & Son, New York, 1975, 1982); P. M. Morse and H. Feshbach, Methods of Theoretical Physics (McGraw-Hill Book Company, Inc., New York, 1953)]. The electric and magnetic fields of a photon arise from the time-dependent quantum probability densities of the orbit and the spin current. This paper is an extension of the semiclassical description of photon emission published by the author earlier in 1999 [M. Kowalski, Phys. Essays 12, 312 (1999)]. In the semiclassical approach, the Coulomb force and a radiation resistance force have been taken into account to get time-dependent emission of the photon. In both the quantum and semiclassical cases, the transition takes place within a time interval equal to one period of the photon's wave. The creation of a one-wavelength-long photon is supported by the results of experiments using ultrafast (ultrashort) laser pulses to generate excited atoms, which emit light pulses shorter than two photon wavelengths [F. Krausz and M. Ivanov, Rev. Mod. Phys. 81, 163 (2009); H. Kapteyn and M. Murnane, Phys. World 12, 31 (1999)].

APA, Harvard, Vancouver, ISO, and other styles

44

Palmroth, M., K. Kuuliala, R. Peltomaa, A. Virtanen, A. Kuuliala, A. Kurttila, A. Kinnunen, M. Leirisalo-Repo, O. Silvennoinen, and P. Isomäki. "AB0250 TOFACITINIB SUPPRESSES SEVERAL JAK-STAT PATHWAYS IN RHEUMATOID ARTHRITIS AND BASELINE SIGNALING PROFILE ASSOCIATES WITH TREATMENT RESPONSE." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1150.2–1151. http://dx.doi.org/10.1136/annrheumdis-2021-eular.448.

Full text

Abstract:

Background:Cytokines are important mediators of inflammation and tissue destruction in rheumatoid arthritis (RA) 1. Several cytokines involved in RA pathogenesis act through Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway 2. The effects of JAK-inhibitor tofacitinib on cytokine signaling in vitro are well established, while in vivo evidence in patients remains scarce.Objectives:To investigate in vivo in rheumatoid arthritis patients i) which JAK-STAT pathways are inhibited by tofacitinib and ii) if baseline signaling profile is associated with the treatment response.Methods:Sixteen patients with active RA, despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), received tofacitinib 5 mg twice daily for three months. Levels of basal and cytokine-induced phosphorylated STATs and total STAT1 and STAT3 in peripheral blood monocytes, T cells and B cells were measured by flow cytometry. mRNA expression of JAKs, STATs and suppressors of cytokine signaling (SOCS) were measured from peripheral blood mononuclear cells (PBMCs) by quantitative PCR. Association of baseline signaling profile with treatment response (the change from baseline in disease activity score (DAS28)) was studied by calculating correlation coefficients.Results:Treatment with tofacitinib and csDMARDs decreased median DAS28 from 4.4 to 2.6 (p < 0.001). Tofacitinib significantly decreased cytokine-induced phosphorylation of all JAK-STAT pathways studied. Basal STAT1, STAT3, STAT4 and STAT5 phosphorylation in monocytes and/or T cells was downregulated by tofacitinib. No changes were observed in STAT1 and STAT3 protein levels, while gene expression of STAT3, STAT4, STAT5A, JAK1, JAK3 and all studied SOCSs was significantly suppressed. Baseline STAT phosphorylation levels in T cells and monocytes and SOCS3 expression in PBMCs correlated with treatment response.Conclusion:Tofacitinib suppresses multiple JAK-STAT pathways in RA patients in vivo. Baseline JAK-STAT signaling profile may be applicable as a prognostic marker for treatment response to tofacitinib.References:[1]McInnes, I. B., Buckley, C. D. & Isaacs, J. D. Cytokines in rheumatoid arthritis-shaping the immunological landscape. Nature Reviews Rheumatology vol. 12 63–68 (2016).[2]Schwartz, D. M., Bonelli, M., Gadina, M. & O’Shea, J. J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat. Rev. Rheumatol.12, 25–36 (2016).Acknowledgements:This study was supported by Pfizer Inc.Disclosure of Interests:Maaria Palmroth Consultant of: Pfizer and from 1/21 a part-time employee of MedEngine and consultant for Pfizer, Krista Kuuliala Grant/research support from: Pfizer, Ritva Peltomaa Speakers bureau: Boehringer Ingelmheim, Pfizer, Sanofi, Paid instructor for: Boehringer Ingelheim, Eli Lilly and Company, Janssen, Abbvie, UCB Pharma, Anniina Virtanen: None declared, Antti Kuuliala: None declared, Antti Kurttila: None declared, Anna Kinnunen: None declared, Marjatta Leirisalo-Repo: None declared, Olli Silvennoinen Speakers bureau: Pfizer, AbbVie, Pia Isomäki Speakers bureau: Abbvie, Eli Lilly and Company, Pfizer, Roche, Paid instructor for: Abbvie, Eli Lilly and Company, Pfizer, Roche, Grant/research support from: Pfizer

APA, Harvard, Vancouver, ISO, and other styles

45

Aitken, R. J. "Mastery of surgery. 3rd ed. (2 volumes). L. M. Nyhus, R. J. Baker and J. E. Fischer (eds). Both volumes: 285 × 220mm. Pp. 2400. Illustrated. 1996. Boston, Massachusetts: Little, Brown and Company. £220." British Journal of Surgery 84, no. 5 (May 1997): 733. http://dx.doi.org/10.1002/bjs.1800840555.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Davidov, Sergey, Aleksandar Krapež, and Yuri Movsisyan. "Functional equations with division and regular operations." Asian-European Journal of Mathematics 11, no. 03 (May 3, 2018): 1850033. http://dx.doi.org/10.1142/s179355711850033x.

Full text

Abstract:

Functional equations are equations in which the unknown (or unknowns) are functions. We consider equations of generalized associativity, mediality (bisymmetry, entropy), paramediality, transitivity as well as the generalized Kolmogoroff equation. Their usefulness was proved in applications both in mathematics and in other disciplines, particularly in economics and social sciences (see J. Aczél, On mean values, Bull. Amer. Math. Soc. 54 (1948) 392–400; J. Aczél, Remarques algebriques sur la solution donner par M. Frechet a l’equation de Kolmogoroff, Pupl. Math. Debrecen 4 (1955) 33–42; J. Aczél, A Short Course on Functional Equations Based Upon Recent Applications to the Social and Behavioral Sciences, Theory and decision library, Series B: Mathematical and statistical methods (D. Reidel Publishing Company, Dordrecht, Boston, Lancaster, Tokyo, 1987); J. Aczél, Lectures on Functional Equations and Their Applications (Supplemented by the author, ed. H. Oser) (Dover Publications, Mineola, New York, 2006); J. Aczél, V. D. Belousov and M. Hosszu, Generalized associativity and bisymmetry on quasigroups, Acta Math. Acad. Sci. Hungar. 11 (1960) 127–136; J. Aczél and J. Dhombres, Functional Equations in Several Variables (Cambridge University Press, New York, 1991); J. Aczél and T. L. Saaty, Procedures for synthesizing ratio judgements, J. Math. Psych. 27(1) (1983) 93–102). We use unifying approach to solve these equations for division and regular operations generalizing the classical quasigroup case.

APA, Harvard, Vancouver, ISO, and other styles

47

Howells, D. A. "Terra non firma, by J. M. Gere and H. C. Shah, W. H. Freeman & Company, New York, 1984, No. of pages: 203. Price: E19.95 (board), £11.95 (paperback)." Earthquake Engineering & Structural Dynamics 13, no. 3 (May 1985): 425. http://dx.doi.org/10.1002/eqe.4290130312.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

McPherson, Kenneth. "Maritime Empires?British Imperial Maritime Trade in the Nineteenth Century - By DAVID KILLINGRAY, MARGARETTE LINCOLN, NIGEL RIGBY and The Worlds of the East India Company - By H. V. BOWEN, M. LINCOLN, N. RIGBY." International Journal of Nautical Archaeology 35, no. 2 (October 2006): 345–46. http://dx.doi.org/10.1111/j.1095-9270.2006.126_3.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Whitfield, William. "Media reviews. Foundations of Psychiatric Mental Health Nursing 3rd edition, edited by Elizabeth M. Varcarolis. WB Saunders Company, Philadelphia, 1998, 2031 pages, f36.00 (hardback) ISBN 0 721 68643 5, f10.00 (paperback) ISBN 0 721 68643 3." Journal of Advanced Nursing 31, no. 4 (April 2000): 983–84. http://dx.doi.org/10.1046/j.1365-2648.2000.1399i.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Hall, Kathryn A. "Treating Alcohol and Drug Abuse in the Elderly. Anne M. Gurnack, Roland Atkinson, and Nancy J. Osgood (Eds.). New York: Springer Publishing Company, 2002, 256 pp., $US 39.95 (hardcover)." International Psychogeriatrics 14, no. 4 (December 2002): 421–23. http://dx.doi.org/10.1017/s1041610202258603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'M. J. Brandenstein and Company'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles